A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer

Trial summary:

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus capecitabine to participants with colorectal cancer.

Receptor status / problem studied:

Inclusion criteria

  • Participant must have measurable disease as defined per RECIST version 1.1
  • Has a histologically confirmed colorectal adenocarcinoma with metastatic or unresectable disease (Stage IV as defined by American Joint Committee on Cancer [AJCC] 8th edition)
  • No prior systemic therapy for colorectal cancer (CRC) in the metastatic setting except for the induction treatment of first-line therapy. Note: Local regional treatment performed during induction systemic treatment is allowed
  • Participants who have completed the first-line induction treatment, with an overall response of stable disease or better

Exclusion criteria

  • Participants whose disease has become resectable at the investigator’s discretion during or after induction treatment are not eligible
  • Induction treatment initiated less than 6 months from completion of any prior neoadjuvant or adjuvant chemotherapy or radiotherapy
  • Participants who have been treated with anti-epidermal growth factor receptor (EGFR) antibody in the induction treatment
  • Any prior therapy targeting T-cell stimulation or checkpoint pathways
  • Participants with documented B-raf proto-oncogene, serine/threonine kinase (BRAF) mutations by local assessments
  • Have locally or centrally confirmed microsatellite instability-high (MSI-H) by polymerase chain reaction (PCR) method or deficient mismatch repair (dMMR) immunohistochemistry (IHC). Local result is recommended and acceptable for enrollment. Participants without local testing results are required to have a central laboratory assessment. Note: CRC patients with tumors without mismatch repair (MMR) deficiency or MSI-H status are categorized as pMMR or microsatellite stable (MSS)

View more trial information

Open for recruitment

Trial Title



Colorectal cancer

Type of trial


Type of treatement

Medical Oncology





Principal Investigator
View all clinical trials


Contact us
Become a patient